Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design
Pharmaceutical Sciences and Drug Design · 2023
DOI: 10.51847/2ucoyf3jpn ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2023. Verfasst von Bing Xie und 4 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Dolutegravir sodium is an effective antiretroviral medication used for the treatment of HIV. The drug is classified as BCS class II, indicating its low solubility at the typical gastric pH. The purpose of this research was to identify and optimize the key operational and formulation factors affecting the drug’s properties, using a 32-factorial design. Nanosuspensions were prepared using PVP K30, polyvinyl alcohol, polxammer 407, and polxammer 188. The study focused on polymer concentration as th
Zitieren
APA
Xie, B., Liu, Y., Li, X., Yang, P., & He, W. (2023). Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design. Pharmaceutical Sciences and Drug Design. https://doi.org/10.51847/2ucoyf3jpn
Vancouver
Xie B, Liu Y, Li X, Yang P, He W. Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design. Pharmaceutical Sciences and Drug Design. 2023. doi:10.51847/2ucoyf3jpn
BibTeX
@article{Xie2023,
author = {Xie, Bing and Liu, Yaping and Li, Xiaotong and Yang, Pei and He, Wei},
title = {Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2023},
doi = {10.51847/2ucoyf3jpn}
}
EUVIMED